PT  - JOURNAL ARTICLE
AU  - Sebastian Bruera
AU  - Xiudong Lei
AU  - Hui Zhao
AU  - Jinoos Yazdany
AU  - Mariana Chavez-MacGregor
AU  - Sharon H Giordano
AU  - Maria E Suarez-Almazor
TI  - Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus
AID  - 10.1136/lupus-2022-000750
DP  - 2023 Feb 01
TA  - Lupus Science & Medicine
PG  - e000750
VI  - 10
IP  - 1
4099  - http://lupus.bmj.com/content/10/1/e000750.short
4100  - http://lupus.bmj.com/content/10/1/e000750.full
SO  - Lupus Sci Med2023 Feb 01; 10
AB  - Objectives We compared the outcomes of patients with or without systemic lupus erythematosus (SLE) who were diagnosed with coronavirus disease 19 (COVID-19) and evaluated factors within patients with SLE associated with severe outcomes.Methods This retrospective cohort study used the deidentified Optum COVID-19 electronic health record dataset to identify patients with COVID-19 from 1/1/2020 to 31/12/2020. Cases with SLE were matched with general controls at a ratio of 1:10 by age, sex, race and ethnicity and COVID-19 diagnosis date. Outcomes included 30-day mortality, mechanical ventilation, hospitalisation and intensive care unit admission. We evaluated the relationship between COVID-19-related outcomes and SLE using multivariable logistic regression. In addition, within SLE cases, we examined factors associated with COVID-19 related outcomes, including disease activity and SLE therapy.Results We included 687 patients matched with 6870 controls. Unadjusted rates of outcomes for patients with SLE were significantly worse than for matched controls including mortality (3.6% vs 1.8%), mechanical ventilation (6% vs 2.5%) and hospitalisation (31% vs 17.7%) (all p<0.001). After multivariable adjustment, patients with SLE had increased risks of mechanical ventilation (OR 1.81, 95% CI 1.16 to 2.82) and hospitalisation (OR 1.32, 95% CI 1.05 to 1.65). Among patients with SLE, severe disease activity was associated with increased risks of mechanical ventilation (OR 5.83, 95% CI 2.60 to 13.07) and hospitalisation (OR 3.97, 95% CI 2.37 to 6.65). Use of glucocorticoids, mycophenolate and tacrolimus before COVID-19 was associated with worse outcomes.Conclusion Patients with SLE had increased risk of severe COVID-19-related outcomes compared with matched controls. Patients with severe SLE disease activity or prior use of corticosteroids experienced worse outcomes.All data relevant to the study are included in the article or uploaded as supplementary information.